Skip to main
KOD

KOD Stock Forecast & Price Target

KOD Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Kodiak Sciences Inc has demonstrated promising advancements in its clinical pipeline, with four active Phase 3 trials for its lead products, including tarcocimab, KSI-501, and KSI-101, and multiple data readouts anticipated through 2026. The company reported an increase in R&D expenses to $50.5 million for the quarter, primarily due to clinical and manufacturing activities, indicative of its ongoing commitment to product development. Encouraging follow-up results from the APEX trial revealed significant improvements in best-corrected visual acuity (BCVA) for patients, which could strengthen the company's position in the competitive biopharmaceutical market for retinal diseases.

Bears say

The financial outlook for Kodiak Sciences is negatively impacted by several critical factors, including the potential failure of its developmental candidates, particularly Tarcocimab, to meet peak commercial revenue estimates due to limitations related to market size and penetration rates. Additionally, the company reported a significant net loss of $61.5 million for the third quarter of 2025, indicating ongoing cash burn that may hinder its ability to fund operations and expand necessary commercialization infrastructure. Furthermore, there are substantial regulatory and clinical risks associated with the approval of its products, as well as pervasive uncertainties regarding the effectiveness of its ABC technology platform, which could jeopardize the future of key pipeline assets.

KOD has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kodiak Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kodiak Sciences Inc (KOD) Forecast

Analysts have given KOD a Buy based on their latest research and market trends.

According to 6 analysts, KOD has a Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kodiak Sciences Inc (KOD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.